Gastroenterology

Novel tremelimumab-durvalumab regimen safe, effective in advanced liver cancer



A single 300 mg priming dose of tremelimumab in combination with durvalumab appeared safe and active among patients with advanced hepatocellular carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.
The results suggest the regimen has a better benefit-risk profile than tremelimumab administered in 75 mg doses with durvalumab or monotherapy with either drug, researchers noted.
“Immune checkpoint inhibition with anti-PD-L1 and anti-CTLA-4 antibodies drive antitumor activity and have demonstrated durable immune responses in subsets of patients with

Source link

Related posts

When Should I Have a Colon Cancer Screening?

Newsemia

P048 QUALITY OF LIFE AND OTHER PATIENT REPORTED OUTCOMES IN PATIENTS WITH POUCHITIS

Newsemia

A novel technique to prepare a single cell suspension of isolated quiescent human hepatic stellate cells

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World